]. Axi-cel was approved by the FDA for R/R large BCL in 2017 and shortly after by the European Medical Agency in 2018. These approvals were based on optimistic phase-2 results from the ZUMA-1 study that reveal long-term remission and CR rates. Axi-111 cel's patients with refractory LBCL in a phase 2 trial demonstrated an 82% overall response rate and a 54% total response rate.
and TRANSCEND NHL 001 in patients with relapsed and resistant MCL have produced fascinating findings recently. Tablesummarizes various clinical development outcomes for MCL. is a Phase 2, multicenter clinical study that aimed to look at the effectiveness of KTE-X19 in people who have R/R MCL . A CD19-directed CAR T-cell therapy with a co-stimulatory domain of CD28, is used in ZUMA-2 CAR T-cell therapy. The trial started on November 9, 2015, by Kite, a Gilead Company. In phase 2 of the experiment, every brexu-cel goal dose contained 2 folds 106 viable CAR-positive -T cells/kg.